ArticleERJ open research2021
The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands.
Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Epidemiology and Drug Susceptibility of Nontuberculous Mycobacteria in the Province of Pavia (Northern Italy): An Overview.Microorganisms · 2025Article
- Encapsulin protein MAV2054 enhances Mycobacterium avium virulence by promoting Cdc42-dependent epithelial cell invasion.Journal of microbiology (Seoul, Korea) · 2025Article
- The gut-lung axis and microbiome dysbiosis in non-tuberculous mycobacterial infections: immune mechanisms, clinical implications, and therapeutic frontiers.Gut pathogens · 2025Review
- Paediatric cervicofacial lymphadenitis caused by non-tuberculous mycobacteria: nation-wide overview in the period 2000-2020.BMC pediatrics · 2025Article
- The Intriguing Pattern of Nontuberculous Mycobacteria in Bulgaria and Description ofInternational journal of molecular sciences · 2024Article
- Evaluation of a national multidisciplinary meeting for non-tuberculous mycobacterial disease.IJTLD open · 2024Article
- Who is at risk of lung nodules on low-dose CT in a Western country? A population-based approach.The European respiratory journal · 2024Article
- Article
- Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: A Review.Clinics in chest medicine · 2023Review
- Clinical characteristics of patients with non-tuberculous mycobacterial pulmonary disease: a seven-year follow-up study conducted in a certain tertiary hospital in Beijing.Frontiers in cellular and infection microbiology · 2023Article
- Changing Incidence and Characteristics of Nontuberculous Mycobacterial Infections in Scotland and Comparison WithOpen forum infectious diseases · 2023Article
- Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery.Respiratory research · 2022Review
- Variability ofAntibiotics (Basel, Switzerland) · 2022Review
- Nontuberculous Mycobacteria Isolates in Respiratory Samples and Mycobacterial Pulmonary Disease in an Area of Northern Spain.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNontuberculous mycobacteria (NTM) are emerging opportunistic pathogens of humans. Because NTM pulmonary disease (PD) is not a notifiable disease in Europe, the epidemiology of NTM-PD is not well known. However, the prevalence of NTM-PD is thought to be increasing, particularly in countries where tuberculosis rates have decreased. Here we aim to determine the prevalence of NTM-PD in the Netherlands.
methodsAnnual prevalence estimates of NTM-PD in the Netherlands (2012-2019) were derived from four separate databases, including two drug dispensing databases, an ICD-10 code database and a hospitalisation database. Databases covered a fraction of the Dutch population and were extrapolated. In addition, annual NTM-PD prevalence was also estimated by means of a pulmonologist survey.
resultsThe estimated annual prevalence of NTM-PD using databases is between 2.3 and 5.9 patients per 100 000 inhabitants. Prevalence estimates derived from the drug dispensing databases, the hospitalisation database and the claims database were 2.3, 5.9, 3.5 and 4.5 per 100 000 inhabitants, respectively. The annual prevalence estimated in the pulmonologist survey was between 6.2 and 9.9 per 100 000 inhabitants. The annual prevalence remained stable over the included period.
conclusionThe estimated annual prevalence of NTM-PD using databases was between 2.3 and 5.9 patients per 100 000 inhabitants. Due to the possible presence of tuberculosis patients and low coverage in one dispensing database, we believe an annual prevalence of between 2.3 and 4.5 patients per 100 000 inhabitants is more probable, which still renders NTM-PD a serious health threat. This estimate is lower than the estimate from the pulmonologist survey, indicating physicians likely overestimate prevalence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.